List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Europe Genetic Testing Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 84 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 84 pages
- Published: 07-06-2019
Market Overview
Genetic testing has been growing at an unprecedented rate; a large panel of tests are now available to screen a number of genetic diseases. Treatment is available for a number of rare genetic diseases and the procedure is gaining importance in scenarios, such as carrier testing, newborn screening, predictive and pre-symptomatic testing, etc. Technologies, such as next-generation sequencing, allow one to carry out a large number of genetic tests rapidly and create databases with information about rare genetic diseases. The European countries have undertaken a number of initiatives to increase awareness among people about the benefits of genetic testing.
There are a number of favorable and collaborative policies that are being implemented by the governments to incorporate genetic testing into the healthcare system and to make insurance reimbursements available to citizens. Cancer genetic testing, Alzheimer’s disease testing, and cystic fibrosis testing are the most popular screening tests being carried out in Europe. Till date, genetic testing is being done for a majority of 50 identified hereditary cancer syndromes. Out of them, some of the most common ones include hereditary breast cancer and ovarian cancer syndromes, Li-Fraumeni syndrome, Cowden syndrome, Lynch syndrome, Familial adenomatous polyposis, and retinoblastoma, among others. The practice of genetic testing for hereditary cancer syndromes has changed dramatically in the recent years. In developed countries, like Germany, France, etc., the demand for genetic testing to detect cancer risks is driving the growth of the market. The high GDP expenditure on healthcare, per capita expenditure, increase in awareness among the people, and high income of the citizens are the factors that drive the market in European countries.
Scope of the Report
As per the scope of this report, genetic testing is a test performed to identify the presence of a particular gene/s with a particular sequence of the genome. The gene/s can be identified either directly through sequencing or indirectly through various methods.
Key Market Trends
Diagnostic testing is the segment under type of testing that is expected to grow fastest during the forecast period
Predictive and presymptomatic testing dominated the European genetic testing market system, as it is utilized for the detection of gene mutations related to disorders that appear after birth, frequently in later stages of life. Such tests can be of assistance to individuals having a family member with a genetic disorder, though they are free of any features of the disorder while testing.
Diagnostics testing is expected to register a CAGR of 14.29%, as it is used to diagnose or rule out a specific genetic condition. In most cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical mutations and symptoms. Furthermore, companies, such as Centogene and NIMGenetics, offer a wide range of genetic diagnostic services in Europe, which is further accelerating the growth of the market.
Competitive Landscape
The European genetic testing market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
4.2.2 Increasing Demand for Personalized Medicine
4.2.3 Increasing Application of Genetic Testing in Oncology
4.3 Market Restraints
4.3.1 High Costs of Genetic Testing
4.3.2 Social and Ethical Implications of Genetic Testing
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Newborn Screening
5.1.4 Predictive and Presymptomatic Testing
5.1.5 Prenatal Testing
5.1.6 Nutrigenomic Testing
5.2 Disease
5.2.1 Alzheimer’s Disease
5.2.2 Cancer
5.2.3 Cystic Fibrosis
5.2.4 Sickle Cell Anemia
5.2.5 Duchenne Muscular Dystrophy
5.2.6 Thalassemia
5.2.7 Huntington’s Disease
5.2.8 Special Disease
5.2.9 Other Diseases
5.3 Technology
5.3.1 Cytogenetic Testing
5.3.2 Biochemical Testing
5.3.3 Molecular Testing
5.4 Geography
5.4.1 Europe
5.4.1.1 Germany
5.4.1.2 United Kingdom
5.4.1.3 France
5.4.1.4 Italy
5.4.1.5 Spain
5.4.1.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Illumina Inc.
6.1.2 Abbott Laboratories
6.1.3 23andMe Inc.
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Qiagen
6.1.6 Blueprint Genetics Oy
6.1.7 Eurofins Scientific
6.1.8 Centogene AG
6.1.9 Thermo Fisher Scientific
6.1.10 Elitech Group
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Type
Carrier Testing
Diagnostic Testing
Newborn Screening
Predictive and Presymptomatic Testing
Prenatal Testing
Nutrigenomic Testing
Disease
Alzheimer’s Disease
Cancer
Cystic Fibrosis
Sickle Cell Anemia
Duchenne Muscular Dystrophy
Thalassemia
Huntington’s Disease
Special Disease
Other Diseases
Technology
Cytogenetic Testing
Biochemical Testing
Molecular Testing
Geography
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 13-06-2019
Market Overview
The Europe glucagon-like peptide-1 (GLP-1) market is expected to witness tremendous growth during the forecast period (2019-2024), with a CAGR of 14.5%, mainly as a result of new drug launches.
Europe has approximately 56.3 million adults living with diabetes, and this number is expected to reach 70 million by 2023, which would represent around 10% of the total population of Europe.
Europe’s expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway.
Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal.
In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
The European region suffers from a high burden of diabetes, and its adverse health and economic consequences.
The disease is viewed as a serious threat, not just from a public health perspective, but also from a development perspective.
With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries of the region. It is one of the most common chronic diseases in the United Kingdom.
Scope of the Report
The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends
Ever Increasing Burden of Diabetes in the European Region
As there is an exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients.
With the increase in the diabetes population, the need and demand for diabetes drugs are expected to increase.
Other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.
Germany to Dominate the Europe GLP-1 Market
Among the studied countries, Germany is expected to lead the market, with a considerable 27.25% of the market share, followed by France.
Victoza holds the highest market share in the Europe region, and a similar trend is seen in Germany too. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells, suppressing inappropriate elevated glucagon secretion.
Trulicity is expected to have the highest growth during the forecast period (2019-2024) in the Europe region.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding a presence in all the regions.
The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly over the forecast period, because of Trulicity and Ozempic.
Oral Semaglutide, which is in phase 3 clinical trials, is expected to launch by 2020. The product has shown better results than Januvia in studies.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 Europe
5.2.1.1 Germany (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Spain (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Italy (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
5.2.1.4 France (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 UK (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Russia (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
5.2.1 Europe
5.2.1.1 Germany (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Spain (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Italy (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
5.2.1.4 France (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 UK (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Russia (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Europe Telemedicine Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 10-06-2019
Market Overview
The major factors responsible for the growth of the European telemedicine market include the changing socio-economic factors, the higher percentage of digitally literate population, when compared to other geographies, and favorable policies. These factors are further expected to drive the growth of the European telemedicine market during the forecast period.
The higher percentage of digitally literate population, when compared to other geographies, is driving the overall growth of the market in Europe. According to the data published by the Eurostat, more than four fifths (85%) of all households in the EU-28 had internet access in 2016. Between 2007 and 2016, the proportion of households with dependent children (that had access to the internet) was consistently higher than that for households without dependent children. The gap between households with dependent children and those without continued to grow, and thus, a higher percentage of digital literacy was observed in Europe, when compared to other regions. Due to this increase, the use of telemedicine is easier for people in Europe.
In the European Member States, more than four out of every five young people, aged 16-29 years, used a computer on a daily basis, in 2015. There is a 2020 Life Long Learning strategy in Estonia, which has a number of objectives in relation to digital skills, putting in place the infrastructure to ensure all schools have access to technology and internet, as a pre-condition for digital learning.
Nevertheless, the rates of internet access continued to increase year-on-year. Moreover, the daily use of internet in 2016 was consistently higher among young people, than it was for the whole population in each of the EU member states. Hence, the increasing use of internet has helped to drive the telemedicine market in Europe.
Scope of the Report
As per the scope of the report, telemedicine refers to the remote diagnosis and treatment of patients with the help of telecommunication technology. Further, various kinds of telemedicine services, along with devices, have been tracked, in order to determine the market size and forecast. The telemedicine services include tele-education, teleconsultation, telemonitoring, teletraining, telecare, telesurgery, and teleconference. The market has been noticing technological developments on a large scale for the past couple of years. Integration of services, such as EMR, picture archiving and communication systems (PACS), telehealth services, RFID, etc., has been gaining increasing importance in Europe.
Key Market Trends
Telemonitoring Segment under Service is Expected to Account for Fastest Growth Rate during the Forecast Period
The applications of telemonitoring are mainly in treating chronic illnesses, such as cardiopulmonary disease, asthma, and heart failure, at home. Telemonitoring is also a way of responding to the new needs of home care for the aging population. Real-time monitoring of patients in ambulances reduces the time taken to initiate treatment and allows the emergency crew to be better prepared. Telemonitoring moves patient care out of a clinical setting into the patient’s home, by utilizing telecommunication technologies, such as the internet, telephone, or video conferencing, to transmit physiological data and information about current symptoms, from the patient to the healthcare professionals. Telemonitoring programs can be flexible, individually tailored, and have the potential to provide access to specialist care for a larger number of patients, across a much greater geographical region, when compared to usual care. In the future, virtual reality, immersive environments, haptic feedback, and nanotechnology promise new ways of improving the capabilities of telemonitoring. Hence, telemonitoring is expected to help in augmenting the growth of the telemedicine market.
Competitive Landscape
The market comprises few major market players and these players are focusing on technological advancements to acquire the major market share. The market has been noticing technological developments on a large scale for the past couple of years. Integration of services, such as EMR, picture archiving and communication systems (PACS), telehealth services, RFID, etc., has been gaining increasing importance in Europe.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Changing Socio-economic Factors
4.2.2 Higher Percentage of Digitally Literate Population Compared to Other Geographies
4.2.3 Favorable Policies
4.3 Market Restraints
4.3.1 Lack of Interoperability between eHealth Solutions
4.3.2 Inadequate or Fragmented Legal Frameworks, including the Lack of Reimbursement Schemes for eHealth Services
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Service
5.1.1 Tele-education
5.1.2 Teleconsultation
5.1.3 Telemonitoring
5.1.4 Teletraining
5.1.5 Telecare
5.1.6 Telesurgery
5.1.7 Teleconference
5.1.8 Other Services
5.2 By Technology
5.2.1 Hardware
5.2.2 Software
5.2.3 Telecom
5.3 By Specialty Area
5.3.1 Cardiology
5.3.2 Dermatology
5.3.3 Neurology
5.3.4 Gynaecology
5.3.5 Emergency Care
5.3.6 Internal Medicine
5.3.7 Orthopedics
5.3.8 Other Specialty Areas
5.4 Geography
5.4.1 Europe
5.4.1.1 United Kingdom
5.4.1.2 Germany
5.4.1.3 France
5.4.1.4 Italy
5.4.1.5 Spain
5.4.1.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions Inc.
6.1.2 BioTelemetry Inc.
6.1.3 Honeywell Life Sciences
6.1.4 IBM Corporation
6.1.5 Koninklijke Philips NV
6.1.6 McKesson Corporation
6.1.7 Medtronic PLC
6.1.8 SHL Telemedicine Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Service
Tele-education
Teleconsultation
Telemonitoring
Teletraining
Telecare
Telesurgery
Teleconference
Other Services
By Technology
Hardware
Software
Telecom
By Specialty Area
Cardiology
Dermatology
Neurology
Gynaecology
Emergency Care
Internal Medicine
Orthopedics
Other Specialty Area
Geography
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
France Aesthetic Medicine Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 85 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 85 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the market are the growing adoption of non-invasive aesthetic procedures, increasing awareness among customers, and availability of user-friendly aesthetic products.
In France, it has been observed that patients begin anti-ageing techniques and minimally invasive treatments at a very young age, and require more invasive procedures in order to maintain their youthful appearance. Moreover, the rise in disposable income has boosted the demand for cosmetic surgeries, thereby accelerating the market growth.
Along with the increased awareness about the potential benefits of aesthetic procedures, people are also inclined toward the use of minimal or non-invasive procedures in aesthetic treatments. The popularity of non-invasive or minimally invasive techniques is increasing in France. The reason for significant inclination is that the majority of the audiences perceive normal surgical treatments as painful and involved with a high risk factors. Thus, the growing adoption of non- or minimally invasive aesthetic procedures is fueling the growth of the medical aesthetic medicine market in France.
Additionally, there has also been an abundant rise in the advertising, displaying the before’ and after’ difference of various aesthetic procedures, thereby prompting the youth and middle aged to undergo medical aesthetic procedures.
Scope of the Report
As per the scope of the report, aesthetic medicine is defined as the specialties that focus on enhancing cosmetic appearance through the treatment of ageing, infectious, or diseased skin conditions. Aesthetic medicines and cosmetic surgery is a developing clinical subspecialty and field in scientific research, which comprises all kind of medical procedures whose purpose is to improve the physical appearance and satisfaction of the patient, including all non-invasive and minimally invasive cosmetic procedures.
Key Market Trends
Dermal Filler is the Segment by Product that is Expected to Grow the Largest During the Forecast Period
The dermal filler segment has the largest market share, and is expected to continue during the forecast period. The dermal fillers segment is constantly developing in France, and accounts for a sales volume of around 850,000 dermal syringes annually. Absorbable dermal fillers are majorly contributing to the total dermal filler market segment in France, due to its less side effects. On the other hand, the agencies in France are currently not advising the use of non-absorbable products for aesthetic purpose, given the risk of extremely delayed, uncontrollable, and serious adverse effects.
Competitive Landscape
The French aesthetic medicine market is medium consolidated, with some local players competing with international players. The major strategies adopted by most of the key industry players include the new product launches, acquisitions, mergers, and partnerships to strengthen the aesthetics product portfolio and maintain their market position.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Adoption of Non- and Minimally Invasive Aesthetic Procedures
4.2.2 Increasing Awareness among Customers about Cosmetic Procedures
4.2.3 Availability of User-friendly Aesthetic Products
4.3 Market Restraints
4.3.1 Stringent Safety Regulations for Aesthetic Procedures
4.3.2 Risk of Side Effects
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Botulinum Toxin
5.1.2 Dermal Filler
5.1.2.1 Absorbable Dermal Filler
5.1.2.2 Non-absorbable Dermal Filler
5.1.3 Chemical Peel
5.1.4 Microdermabrasion
5.2 By End User
5.2.1 Office Facilities
5.2.2 Hospitals
5.2.3 Other End Users
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan PLC
6.1.2 Bioxis Pharmaceuticals
6.1.3 Dermaceutic Laboratoire
6.1.4 Ipsen Pharma
6.1.5 Johnson & Johnson
6.1.6 Nestle Skin Health
6.1.7 Merz Pharma Gmbh & Co. Kgaa
6.1.8 Laboratoires Filorga
6.1.9 Teoxane Laboratories
6.1.10 Laboratories Vivacy
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product
Botulinum Toxin
Dermal Filler
Absorbable Dermal Filler
Non-absorbable Dermal Filler
Chemical Peel
Microdermabrasion
By End User
Office Facilities
Hospitals
Other End Users
Global Self-Monitoring Blood Glucose Market (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 105 pages | Published: 11-06-2019 |
- Healthcare
- Mordor Intelligence
- 105 pages
- Published: 11-06-2019
Market Overview
One of the fastest-growing chronic diseases in the world is diabetes. Diabetes is a disease that occurs when the glucose levels of the body increase to more than the normal level, and the body unable to produce insulin. Hence, glucometers are used to monitor glucose levels. The Type 1 diabetes population around the world is rising while witnessing a CAGR of 2.13%. As the diabetic population rises, the self-monitoring blood glucose devices market is also bound to increase.
Other factors, such as technological innovations, the convenience of conventional glucose monitoring over conventional monitoring, and early detection of hypo- and hyperglycemic diabetes are the major drivers for market growth.
Scope of the Report
The report includes a complete study on self-monitoring blood glucose, which includes glucometer devices, blood glucose test strips, and lancets. The study is further divided into hospital usage and home usage.
Key Market Trends
Most of the Glucometer Market Revenue is Generated from Blood Glucose Test Strips
Glucometer is considered to be a one-time purchase. However, test strips, on the other hand, are considered to be a continuous investment, as a test strip needs to be disposed off after one use. Thus, it presents a considerable cost impact to the consumers.
Overall, the global demand for blood glucose test strips is projected to witness significant growth over the forecast period. The growth of the market studied is expected to be spurred by the rising global diabetic population.
The growth in market volumes and share of the test strip is expected to be better than that of glucometers, because of the difference in the use-case frequency. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost, during the same time frame, the corresponding use of multiple (in the range of thousands) test strips may occur, causing a recurrent cost impact.
North America has the Largest Market Share, and will Continue to Do So in the Future
The global self-monitoring blood glucose systems market is currently experiencing a boost because diabetic patients have to test their glucose levels throughout the day. Mainly Type 1 diabetic people must, and should, test their blood glucose at least three times per day to take their insulin dosage.
The countries in the North American region have a high prevalence of diabetes. According to WHO in 2015, approximately 1.6 million deaths were attributed directly to diabetes on a global scale. An additional 2.2 million deaths were caused due to high blood glucose in 2012.
According to the ADA (American Diabetes Association), the total assessed cost for diagnosed diabetes in 2017 was USD 327 billion, which was inclusive of USD 237 billion in direct medical costs and USD 90 billion in augmented productivity.
The prevalence of diabetes has increased dramatically during the past two decades, which is a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States.
Competitive Landscape
The global self-monitoring blood glucose market is highly consolidated, with few major manufacturers having a global market presence, while the remaining manufacturers confine to the other local or region-specific manufacturers.
Mergers and acquisitions that occurred between the players in the recent past helped the companies to strengthen their market presence. Panasonic acquired Bayer’s diabetes care unit and named it as Ascensia diabetes care, which continued its operations all over the world.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Self-blood Glucose Monitors
5.1.1 By Component (Market Size, Value, and Volume)
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 By End User
5.1.2.1 Hospital USE (Market Size, Value, and Volume)
5.1.2.1.1 Glucometer Devices
5.1.2.1.2 Test Strips
5.1.2.1.3 Lancets
5.1.2.2 Personal Use (Market Size, Value, and Volume)
5.1.2.2.1 Glucometer Devices
5.1.2.2.2 Test Strips
5.1.2.2.3 Lancets
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Market Size, Value, and Volume)
5.2.1.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.1.1.2 By End User (Hospital Use and Home Use)
5.2.1.1.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.2 Canada (Market Size, Value, and Volume)
5.2.1.2.1 By Component (Glucometer Devices, Test Strips, Lancets)
5.2.1.2.2 By End User (Hospital Use and Home Use)
5.2.1.2.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.3 Rest of North America(Market Size, Value, and Volume)
5.2.1.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.1.3.2 By End User (Hospital Use and Home Use)
5.2.1.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2 Europe
5.2.2.1 France (Market Size, Value, and Volume)
5.2.2.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.1.2 By End User (Hospital Use and Home Use)
5.2.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.2 Germany (Market Size, Value, and Volume)
5.2.2.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.2.2 By End User (Hospital Use and Home Use)
5.2.2.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.3 Italy (Market Size, Value, and Volume)
5.2.2.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.3.2 By End User (Hospital Use and Home Use)
5.2.2.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.4 Spain (Market Size, Value, and Volume)
5.2.2.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.4.2 By End User (Hospital Use and Home Use)
5.2.2.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.5 United Kingdom(Market Size, Value, and Volume)
5.2.2.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.5.2 By End User (Hospital Use and Home Use)
5.2.2.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.6 Russia(Market Size, Value, and Volume)
5.2.2.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.6.2 By End User (Hospital Use and Home Use)
5.2.2.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.7 Rest of Europe (Market Size, Value, and Volume)
5.2.2.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.7.2 By End User (Hospital Use and Home Use)
5.2.2.7.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.3 Latin America
5.2.3.1 Mexico (Market Size, Value, and Volume)
5.2.3.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.3.1.2 By End User (Hospital Use and Home Use)
5.2.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.3.2 Brazil(Market Size, Value, and Volume)
5.2.3.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.3.2.2 By End User (Hospital Use and Home Use)
5.2.3.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.3.3 Rest of Latin America (Market Size, Value, and Volume)
5.2.3.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.3.3.2 By End User (Hospital Use and Home Use)
5.2.3.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Market Size, Value, and Volume)
5.2.4.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.1.2 By End User (Hospital Use and Home Use)
5.2.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.2 South Korea (Market Size, Value, and Volume)
5.2.4.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.2.2 By End User (Hospital Use and Home Use)
5.2.4.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.3 China (Market Size, Value, and Volume)
5.2.4.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.3.2 By End User (Hospital Use and Home Use)
5.2.4.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.4 India (Market Size, Value, and Volume)
5.2.4.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.4.2 By End User (Hospital Use and Home Use)
5.2.4.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.5 Australia (Market Size, Value, and Volume)
5.2.4.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.5.2 By End User (Hospital Use and Home Use)
5.2.4.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.6 Vietnam (Market Size, Value, and Volume)
5.2.4.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.6.2 By End User (Hospital Use and Home Use)
5.2.4.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.7 Malaysia (Market Size, Value, and Volume)
5.2.4.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.7.2 By End User (Hospital Use and Home Use)
5.2.4.7.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.8 Indonesia( Market Size, Value, and Volume)
5.2.4.8.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.8.2 By End User (Hospital Use and Home Use)
5.2.4.8.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.9 Philippines (Market Size, Value, and Volume)
5.2.4.9.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.9.2 By End User (Hospital Use and Home Use)
5.2.4.9.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.10 Thailand (Market Size, Value, and Volume)
5.2.4.10.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.10.2 By End User (Hospital Use and Home Use)
5.2.4.10.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.11 Rest of Asia-Pacific (Market Size, Value, and Volume)
5.2.4.11.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.11.2 By End User (Hospital Use and Home Use)
5.2.4.11.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Market Size, Value, and Volume)
5.2.5.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.1.2 By End User (Hospital Use and Home Use)
5.2.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.2 Iran (Market Size, Value, and Volume)
5.2.5.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.2.2 By End User (Hospital Use and Home Use)
5.2.5.2.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.3 Egypt (Market Size, Value, and Volume)
5.2.5.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.3.2 By End User (Hospital Use and Home Use)
5.2.5.3.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.4 Oman (Market Size, Value, and Volume)
5.2.5.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.4.2 By End User (Hospital Use and Home Use)
5.2.5.4.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.5 South Africa (Market Size, Value, and Volume)
5.2.5.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.5.2 By End User (Hospital Use and Home Use)
5.2.5.5.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.6 Rest of Middle & Africa (Market Size, Value, and Volume)
5.2.5.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.6.2 By End User (Hospital Use and Home Use)
5.2.5.6.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Arkray
7.1.5 Ascensia Diabetes Care
7.1.6 Agamatrix Inc.
7.1.7 Bionime Corporation
7.1.8 Acon
7.1.9 Medisana
7.1.10 Trivida
7.1.11 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Self-blood Glucose Monitors
By Component (Market Size, Value, and Volume)
Glucometer Devices
Test Strips
Lancets
By End User
Hospital USE (Market Size, Value, and Volume)
Glucometer Devices
Test Strips
Lancets
Personal Use (Market Size, Value, and Volume)
Glucometer Devices
Test Strips
Lancets
Geography
North America
United States (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Canada (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Rest of North America(Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Europe
France (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Germany (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Italy (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Spain (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
United Kingdom(Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Russia(Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Rest of Europe (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Latin America
Mexico (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Brazil(Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Rest of Latin America (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Asia-Pacific
Japan (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
South Korea (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
China (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
India (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Australia (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Vietnam (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Malaysia (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Indonesia( Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Philippines (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Thailand (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Rest of Asia-Pacific (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Middle East & Africa
Saudi Arabia (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Iran (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Egypt (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Oman (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
South Africa (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Rest of Middle & Africa (Market Size, Value, and Volume)
By Component (Glucometer Devices, Test Strips, and Lancets)
By End User (Hospital Use and Home Use)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Glucagon like Peptide 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
The glucagon-like peptide-1 (GLP-1) agonists market is expected to see a considerable amount of growth during the forecast period. The increase is mainly attributed to the improved efficiency of GLP-1.
Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and inactivity levels among people.
In addition, lowering birth rates, along with increasing life expectancy, in countries like Japan, Italy, Germany, and France which have a high percentage of the geriatric population, are expected to drive the growth of the market.Novo Nordisk Victoza held a 55% market share in the GLP-1 agonist market in 2017, but it is expected that Eli Lilly’s Trulicity will dominate the market during the forecast period.
Scope of the Report
The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) and by geography.
Key Market Trends –
Constant Global Trend of High Diabetes Prevalence
The sales of GLP-1 are directly proportional to the global trend of high diabetes prevalence.
For instance, the percentages of type 2 diabetes in a few significant countries are as follows: China 22.8%, Oman 17.2%, Malaysia 12.9%, and so on.
It is estimated, worldwide, that approximately USD 8.39 billion is spent on diabetes. The growth in the number of middle-class households, as well as increasing per capita income in these countries, are expected to result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
Along with this, a few critical factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.
North America to Dominate the Market in Terms of Revenue
North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.
In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.
In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding a presence in all regions.
Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Teva confirmed generic Victoza and announced that it had filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA), seeking approval to market the generic version of Novo Nordisk’s Victoza® (liraglutide) injection, in the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 North America
5.2.1.1 US (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2 Europe
5.2.2.1 Germany (Value and Volume 2012-2024)
5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.2 Spain (Value and Volume 2012-2024)
5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.3 Italy (Value and Volume 2012-2024)
5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.4 France (Value and Volume 2012-2024)
5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.5 UK (Value and Volume 2012-2024)
5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.6 Russia (Value and Volume 2012-2024)
5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3 Asia-Pacific
5.2.3.1 Japan (Value and Volume 2012-2024)
5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.2 China (Value and Volume 2012-2024)
5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.3 Australia (Value and Volume 2012-2024)
5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.4 India (Value and Volume 2012-2024)
5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.5 South Korea (Value and Volume 2012-2024)
5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.6 Malaysia (Value and Volume 2012-2024)
5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.7 Indonesia (Value and Volume 2012-2024)
5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.8 Thailand (Value and Volume 2012-2024)
5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.9 Philippines (Value and Volume 2012-2024)
5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4 Latin America
5.2.4.1 Brazil (Value and Volume 2012-2024)
5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4.2 Mexico (Value and Volume 2012-2024)
5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5 Middle East & Africa
5.2.5.1 South Africa (Value and Volume 2012-2024)
5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.3 Oman (Value and Volume 2012-2024)
5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.4 Egypt (Value and Volume 2012-2024)
5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.5 Iran (Value and Volume 2012-2024)
5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
North America
US (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Canada (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of North America (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Europe
Germany (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Spain (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Italy (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
(Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
France (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
UK (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Russia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Europe (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
China (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Australia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
India (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Korea (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Malaysia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Indonesia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Thailand (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Philippines (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Latin America
Brazil (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Mexico (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Latin America (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Middle East & Africa
South Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Oman (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Egypt (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Iran (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)